Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 4,000 Shares

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 4,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at $1,433,183.76. This represents a 29.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Natera Stock Up 4.0 %

NTRA stock opened at $148.22 on Friday. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market cap of $20.04 billion, a PE ratio of -84.22 and a beta of 1.80. The business has a 50 day moving average of $163.70 and a 200 day moving average of $148.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on NTRA shares. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Tuesday, March 11th. Barclays started coverage on Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective on the stock. The Goldman Sachs Group increased their target price on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Guggenheim increased their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Finally, Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $178.12.

Institutional Trading of Natera

Institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC increased its holdings in shares of Natera by 27.0% in the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera in the 3rd quarter worth $385,000. Everence Capital Management Inc. bought a new stake in shares of Natera in the 4th quarter worth $573,000. Alpha DNA Investment Management LLC bought a new stake in shares of Natera in the 3rd quarter worth $505,000. Finally, First Turn Management LLC bought a new stake in shares of Natera in the 3rd quarter worth $19,760,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.